Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Decreases By 62.7%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant decrease in short interest in February. As of February 15th, there was short interest totalling 15,500 shares, a decrease of 62.7% from the January 31st total of 41,500 shares. Based on an average daily trading volume, of 143,200 shares, the short-interest ratio is presently 0.1 days. Approximately 1.0% of the shares of the stock are sold short.

Institutional Trading of Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC acquired a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned 1.08% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is owned by institutional investors and hedge funds.

Sonoma Pharmaceuticals Stock Up 3.2 %

Shares of NASDAQ:SNOA traded up $0.07 during trading on Friday, hitting $2.27. 25,438 shares of the company were exchanged, compared to its average volume of 43,747. The business’s 50 day moving average is $2.61 and its 200-day moving average is $2.61. The company has a market capitalization of $3.67 million, a P/E ratio of -0.56 and a beta of 1.43. Sonoma Pharmaceuticals has a 1-year low of $2.15 and a 1-year high of $9.37.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Wednesday, February 5th. The company reported ($0.59) earnings per share (EPS) for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 68.98% and a negative net margin of 26.82%. As a group, sell-side analysts anticipate that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current year.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.